African scientists begin trial on malaria vaccine
Scientists in Africa have begun trials of a malaria vaccine which, if successful, could save millions of lives on the continent and around the world. The mosquirix vaccine also known as RDSS is being tested in Africa's biggest ever clinical trial, spanning seven nations, and involving over 16 thousand children.
Reports say more than five thousand have already undergone preliminary trials since testing began in 2003.
The vaccine is the result of a partnership between GlaxoSmithKline the British drug manufacturer, and US-based path Malaria Vaccine Imitative which is funded by the Bill and Melinda Gates Foundation along with clinics and research centres in Africa.